DK2968301T3 - Kombination af to antiviraler til behandling af hepatitis c - Google Patents
Kombination af to antiviraler til behandling af hepatitis c Download PDFInfo
- Publication number
- DK2968301T3 DK2968301T3 DK14719977.2T DK14719977T DK2968301T3 DK 2968301 T3 DK2968301 T3 DK 2968301T3 DK 14719977 T DK14719977 T DK 14719977T DK 2968301 T3 DK2968301 T3 DK 2968301T3
- Authority
- DK
- Denmark
- Prior art keywords
- daas
- weeks
- compound
- patient
- hcv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Mindst to direkte virkende antivirale midler (DAA'er) til anvendelse i en fremgangsmåde til at behandle en HCV-infektion, hvilken fremgangsmåde omfatter at administrere mindst to DAA'er til en HCV-patient, hvor hverken interferon eller ribavirin administreres til den nævnte patient under den nævnte behandling, og hvilken behandling varer i 8, 9, 10, 11 eller 12 uger, og hvor de mindst to DAA'er omfatter:
eller et farmaceutisk acceptabelt salt deraf og
eller et farmaceutisk acceptabelt salt deraf.
2. Mindst to DAA'er til anvendelsen ifølge krav 1, hvor den nævnte behandling varer i 12 uger.
3. Mindst to DAA'er til anvendelsen ifølge krav 1, hvor den nævnte behandling varer i 8 uger.
4. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er inficeret med HCV-genotype 1.
5. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er inficeret med HCV-genotype la.
6. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er inficeret med HCV-genotype 2.
7. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er inficeret med HCV-genotype 3.
8. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er inficeret med HCV-genotype 4.
9. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er inficeret med HCV-genotype 5.
10. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er inficeret med HCV-genotype 6.
11. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er uden cirrhose.
12. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er med kompenseret cirrose.
13. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er en behandlings-naiv patient.
14. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor den nævnte patient er en interferon-ikke-responder.
15. Mindst to DAA'er til anvendelsen ifølge et hvilket som helst af kravene 1-14, hvor de nævnte mindst to DAA'er består af (1) forbindelse 1 eller et farmaceutisk acceptabelt salt deraf og (2) forbindelse 2 eller et farmaceutisk acceptabelt salt deraf.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783376P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027423 WO2014152514A1 (en) | 2013-03-14 | 2014-03-14 | Combination of two antivirals for treating hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2968301T3 true DK2968301T3 (da) | 2017-07-24 |
Family
ID=50588882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14719977.2T DK2968301T3 (da) | 2013-03-14 | 2014-03-14 | Kombination af to antiviraler til behandling af hepatitis c |
| DK17165207.6T DK3213750T3 (da) | 2013-03-14 | 2014-03-14 | Kombination af to antivirale midler til behandling af hepatitis c |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17165207.6T DK3213750T3 (da) | 2013-03-14 | 2014-03-14 | Kombination af to antivirale midler til behandling af hepatitis c |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140275099A1 (da) |
| EP (3) | EP2968301B1 (da) |
| JP (4) | JP6441303B2 (da) |
| KR (2) | KR102210935B1 (da) |
| CN (2) | CN105073113B (da) |
| AU (2) | AU2014239563B2 (da) |
| BR (1) | BR112015023017B1 (da) |
| CA (1) | CA2901810C (da) |
| CY (2) | CY1119025T1 (da) |
| DK (2) | DK2968301T3 (da) |
| EA (2) | EA033257B1 (da) |
| ES (2) | ES2824473T3 (da) |
| HK (2) | HK1223817A1 (da) |
| HR (2) | HRP20171036T1 (da) |
| HU (2) | HUE052113T2 (da) |
| IL (1) | IL240419B (da) |
| LT (2) | LT3213750T (da) |
| MX (2) | MX362616B (da) |
| NZ (2) | NZ719137A (da) |
| PL (2) | PL3213750T3 (da) |
| PT (2) | PT2968301T (da) |
| RS (2) | RS60881B1 (da) |
| SG (2) | SG11201507364SA (da) |
| SI (2) | SI3213750T1 (da) |
| TW (2) | TWI642436B (da) |
| WO (1) | WO2014152514A1 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6441303B2 (ja) | 2013-03-14 | 2018-12-19 | アッヴィ・インコーポレイテッド | Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用 |
| WO2017007934A1 (en) * | 2015-07-08 | 2017-01-12 | Abbvie Inc. | Methods for treating hcv |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| CN106456621A (zh) * | 2013-03-14 | 2017-02-22 | 艾伯维公司 | 用于治疗hcv的方法 |
| CA2916912A1 (en) * | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
| MX2016005393A (es) * | 2013-10-25 | 2016-08-11 | Abbvie Inc | Metodos para tratar vhc. |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| CN112704726A (zh) * | 2014-04-02 | 2021-04-27 | 艾伯维公司 | 治疗hcv的方法 |
| CR20180030A (es) * | 2015-06-26 | 2018-05-24 | Abbvie Inc | Composiciones farmacéuticas sólidas para el tratamiento del vhc. |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| US20230385268A1 (en) * | 2022-05-17 | 2023-11-30 | Abbvie Inc. | Methods for Treating HCV |
| CN108024964B (zh) * | 2015-07-17 | 2022-05-03 | 艾伯维公司 | 用于治疗hcv的固体药物组合物 |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CA3037719A1 (en) * | 2016-09-23 | 2018-03-29 | Abbvie Inc. | Dose adjustment |
| CA2994496A1 (en) * | 2017-02-14 | 2018-08-14 | Abbvie Inc. | Methods for treating hcv |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| EP3773753A4 (en) * | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| WO2020106835A1 (en) | 2018-11-20 | 2020-05-28 | Abbvie Inc. | Methods for treating acute hcv |
| KR102077833B1 (ko) | 2018-12-10 | 2020-02-14 | 류형준 | 기능성 식품조성물 |
| CN111688355B (zh) | 2019-03-15 | 2022-04-12 | 精工爱普生株式会社 | 液体吸收体、液体吸收器以及液体喷出装置 |
| BR112021020222A2 (pt) * | 2019-04-08 | 2021-12-21 | Abbvie Inc | Composições farmacêuticas sólidas para tratar hcv |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394279B2 (en) * | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| NZ608720A (en) | 2010-09-21 | 2015-03-27 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| US8330139B2 (en) | 2011-03-25 | 2012-12-11 | Micron Technology, Inc. | Multi-level memory cell |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| ES2527544T1 (es) | 2011-10-21 | 2015-01-26 | Abbvie Inc. | Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC |
| SG10201702248UA (en) * | 2012-09-18 | 2017-04-27 | Abbvie Inc | Methods for treating hepatitis c |
| JP6441303B2 (ja) | 2013-03-14 | 2018-12-19 | アッヴィ・インコーポレイテッド | Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用 |
-
2014
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/ja active Active
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en active Application Filing
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 RS RS20201198A patent/RS60881B1/sr unknown
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/ko active IP Right Grant
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/zh not_active Expired - Fee Related
- 2014-03-14 TW TW103109530A patent/TWI642436B/zh not_active IP Right Cessation
- 2014-03-14 EA EA201591702A patent/EA033257B1/ru unknown
- 2014-03-14 PT PT147199772T patent/PT2968301T/pt unknown
- 2014-03-14 SI SI201431674T patent/SI3213750T1/sl unknown
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/hu unknown
- 2014-03-14 PL PL17165207T patent/PL3213750T3/pl unknown
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/zh active Pending
- 2014-03-14 SI SI201430265A patent/SI2968301T1/sl unknown
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 EA EA201991174A patent/EA201991174A1/ru unknown
- 2014-03-14 MX MX2015012538A patent/MX362616B/es active IP Right Grant
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 ES ES17165207T patent/ES2824473T3/es active Active
- 2014-03-14 PT PT171652076T patent/PT3213750T/pt unknown
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/pt active IP Right Grant
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/es active Active
- 2014-03-14 TW TW107108651A patent/TWI686196B/zh not_active IP Right Cessation
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/lt unknown
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/lt unknown
- 2014-03-14 RS RS20170672A patent/RS56202B1/sr unknown
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/da active
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/da active
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/ko active Application Filing
- 2014-03-14 PL PL14719977T patent/PL2968301T3/pl unknown
-
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/es unknown
-
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
- 2016-07-20 HK HK16108631.0A patent/HK1223817A1/zh unknown
- 2016-07-20 HK HK18103210.8A patent/HK1244668A1/zh unknown
-
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/el unknown
- 2017-07-06 HR HRP20171036TT patent/HRP20171036T1/hr unknown
-
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/ja active Active
-
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/ja active Pending
-
2020
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/el unknown
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/hr unknown
-
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016202823B2 (en) | Combination of two antivirals for treating Hepatitis C | |
| AU2018202581B2 (en) | Combination of direct acting antiviral agents and ribavirin for treating HCV patients | |
| AU2015240754B2 (en) | Methods for treating HCV | |
| AU2020202560A1 (en) | Methods for treating HCV | |
| CA3078939A1 (en) | Methods for treating hcv |